Shark VNAR antibodies neutralize SARS-CoV-2 infection

Single domain shark VNAR antibodies neutralize SARS-CoV-2 infection in vitro

Aziz Gauhar, Cyril V Privezentzev, Mykhaylo Demydchuk, Tanja Gerlza, Julia Rieger, Andreas J Kungl, Frank S Walsh, J Lynn Rutkowski, Pawel Stocki

ABSTRACT:

Single domain shark VNAR antibodies can offer a viable alternative to conventional Ig-based monoclonal antibodies in treating COVID-19 disease during the current pandemic. Here we report the identification of neutralizing single domain VNAR antibodies selected against the SARS-CoV-2 spike protein derived from the Wuhan variant using phage display. We identified 56 unique binding clones that exhibited high affinity and specificity to the spike protein. Of those, 10 showed an ability to block both the spike protein receptor binding domain from the Wuhan variant and the N501Y mutant from interacting with recombinant ACE2 receptor in vitro. In addition, 3 antibody clones retained in vitro blocking activity when the E484K spike protein mutant was used. The inhibitory property of the VNAR antibodies was further confirmed for all 10 antibody clones using ACE2 expressing cells with spike protein from the Wuhan variant. The viral neutralizing potential of the VNAR clones was also confirmed for the 10 antibodies tested using live Wuhan variant virus in in vitro cell infectivity assays. Single domain VNAR antibodies due to their low complexity, small size, unique epitope recognition and formatting flexibility should be a useful adjunct to existing antibody approaches to treat COVID-19.

bioRxiv, DOI: 10.1101/2021.06.08.447530

SOURCE